Skip to Main content Skip to Navigation
Journal articles

Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells

Abstract : The effect of anti-HIV-1 antibodies on complement activation at the surface of infected cells remains partly understood. Here, we show that a subset of anti-Envelope (Env) broadly neutralizing antibodies (bNAbs), targeting the CD4 binding site and the V3 loop, triggers C3 deposition and complement-dependent cytotoxicity (CDC) on Raji cells engineered to express high surface levels of HIV-1 Env. Primary CD4 T cells infected with laboratory-adapted or primary HIV-1 strains and treated with bNAbs are susceptible to C3 deposition but not to rapid CDC. The cellular protein CD59 and viral proteins Vpu and Nef protect infected cells from CDC mediated by bNAbs or by polyclonal IgGs from HIV-positive individuals. However, complement deposition accelerates the disappearance of infected cells within a few days of culture. Altogether, our results uncover the contribution of complement to the antiviral activity of anti-HIV-1 bNAbs.
Document type :
Journal articles
Complete list of metadata
Contributor : Timothée Bruel Connect in order to contact the contributor
Submitted on : Thursday, May 27, 2021 - 3:57:16 PM
Last modification on : Monday, September 5, 2022 - 2:44:06 PM
Long-term archiving on: : Saturday, August 28, 2021 - 7:49:26 PM


Explicit agreement for this submission





Jérémy Dufloo, Florence Guivel-Benhassine, Julian Buchrieser, Valérie Lorin, Ludivine Grzelak, et al.. Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells. EMBO Reports, EMBO Press, 2019, 21 (2), pp.e49351. ⟨10.15252/embr.201949351⟩. ⟨pasteur-03239697⟩



Record views


Files downloads